The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Thomas Jefferson University joins TriNetX research network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THOMAS JEFFERSON UNIVERSITY joined the TriNetX network for clinical trial design and to support Jefferson’s clinical research programs.

Pharmaceutical researchers will be able to access Jefferson’s de-identified clinical data through TriNetX’s network of healthcare institutions to support clinical study and protocol design, site selection, and patient recruitment across a range of therapeutic areas and development stages.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
By Claire Marie Porter and Paul Goldberg
Guest Editorial

How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care

Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more
By Kathy Davy
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account